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SUMMARY
Objective: To study the relationship of the presence of secondary SS with disease activity, 
duration in RA. Methods: Eighty two patients with RA were submitted to Schirmer test, 
minor salivary gland biopsy, questionnaire on sicca symptoms, DAS-28 4v determina-
tion. Results: In this population, 20 (24.3%) patients fulfilled the American-European 
classification criteria for secondary SS. No relation could be found between the presence 
of secondary SS and disease activity (p = 0.31) and RA duration (p = 0.95). Conclusion: 
Appearance of Secondary SS in RA patients is independent of RA duration or activity. 
Keywords: Arthritis, rheumatoid; dry eye syndromes; inflammation.
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INTRODUCTION
Sjögren’s syndrome (SS) is a chronic autoimmune in-
flammatory disease that aects lachrymal and salivary 
glands causing mucous dryness that aects mainly mid-
dle aged women1. SS can be a primary or a secondary 
disease when it is associated with other autoimmune 
disorders such as scleroderma and rheumatoid arthritis 
(RA)2. Superimposed SS in RA is an interesting finding. 
 ere is an important role of B cells and type I interferon 
in primary SS2,3 in contrast to the predominance of  17 
cytokines in RA4. As the physiopathology of these two 
diseases is distinct, it is possible to suggest that patients 
with RA and secondary SS have two dierent diseases 
or that RA secondary SS has a dierent physiopathol-
ogy than the primary form. In this context we aimed to 
study if RA disease activity or severity have any associa-
tion with occurrence of secondary Sjogren’s syndrome.
METHODS
  is study was approved by the Committee for Ethics in 
Research of our institution and all participants signed 
consent. To participate in the study patients had to 
present at least four criteria of the American College of 
Rheumatic Diseases for RA7.   e included patients were 
selected from a single Rheumatology Clinic (Evangelic 
University Hospital) chosen according to appointment 
order and willingness to participate in the study. We ex-
cluded patients with ophthalmologic complications such 
as scleritis, episcleritis, scleromalacia, those with prior 
eye surgery and contact lenses users or those taking 
medications such as antidepressants, anticholinergics, 
antihistamine, diuretics, etc, those with hepatitis C or 
HIV infection or prior irradiation of the neck. 
All included patients had Schirmer test done accord-
ing to standard recommendations and we considered a 
patient to be with definitive dry eye when values were 
equal or under 5 mm in at least one eye8.  Biopsy of mi-
nor salivary gland was done in all included patients and 
sections were stained by hematoxylin-eosin and consid-
ered positive when a focus of 50 lymphocytes/4 mm2 was 
found9. Salivary gland biopsy was read by a blinded pa-
thologist.  Simultaneously with eye tests and minor sali-
vary gland biopsy, patients had DAS-28 4v10,11 and also 
answered a questionnaire on sicca symptoms (oral and 
ocular). DAS 28 is a measurement of RA disease activity 
that takes into account number of swollen and tender 
joints, a measurement of general health by the patients 
and values of sedimentation rate. Patients with DAS28 
values under 2.6 are considered under remission, with 
values between 2.6 and 3.1 as having mild disease activ-
ity; with values between 3.2 and 5.1 as having moderate 
activity and over 5.1 with high disease activity.
Patient’s joint count was done by just one rheuma-
tologist. Charts were reviewed for demographic data, 
HAQ12 and autoantibody profile (latex, anti CCP, anti 
Ro, Anti La). 
To consider a RA patient as having secondary SS it 
was necessary to fulfill the American European Criteria 
for secondary SS13,14.
Data were grouped in contingency and frequency 
table. For association studies we used the chi-squared 
test for nominal data and unpaired t and Mann-Whitney 
tests for numeric data.   e significance adopted was 5%.
RESULTS
Eighty two patients were included: 72 women and 10 
men with mean age of 51.8 ± 10.0 years and mean dis-
ease duration of 10.2  ±  7.0 years. In this sample 50/82 
(75%) had rheumatoid factor; 25/35 (71.4%) had a posi-
tive anti- CCP; 25/82 (30.4%) were ANA positive; 6/82 
(7.3%) had anti-Ro and 1/82 (1.2%) had anti-La. RA 
treatment was done with prednisone in 62/82 (75.6%); 
antimalarials in 63/82 (76.8%); methotrexate in 71/82 
(86.5%), leflunomide in 33/82 (40.2%), sulphasalazine 
in 11/82 (13.4%), anti TNF-   in 8/82 (9.7%) and ritux-
imab in 2/82 (2.4%). Dry eye complaints were found in 
47/82 (57.3%) and dry mouth in 29/82 (35.3%); 46/82 
(56.0%) had a positive minor salivary gland biopsy.   e 
Schirmer test result varied between 0 to 35 mm (mean 
14.3 ± 10.1 mm) and was under 5 mm in 34/82 (41.4%). 
Five (6%) patients had also ceratitis. DAS-28 varied from 
0.6 to 6.99 (mean 3.22 ± 1.41). Twenty patients (24.39%) 
fulfilled the American-European criteria for Secondary SS.
Studying DAS-28 according to the presence of sec-
ondary SS, we found a mean value of 2.81 ± 1.14 in those 
with SS and 3.35 ± 1.47 in those without it (p = 0.13). 
  e mean value of DAS-28 in patients with Schirmer 
test under 5 mm was 3.1 ± 1.3 and in those with values 
higher than 5 mm it was 3.3 ± 1.4 (p = 0.50). Presence of 
Secondary SS according to DAS-28 is shown in Figure 1. 
Mean DAS-28 value in patients with subjective symp-
toms for dry eyes was 3.35 ± 1.58 and in those without it 
3.04 ± 1.13 (p = 0.31).
Figure 1 – Presence of secondary Sjögren’s syndrome 
according to DAS-28 in 82 patients with rheumatoid 
arthritis (p = 0.61).
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Table 1 shows data in RA patients with and without 
Secondary SS Syndrome.
DISCUSSION
 e presence of sicca symptoms was high in the studied 
population although only 24% of patients fulfilled criteria 
for secondary SS.  e high prevalence of dry eyes in RA 
patients without fulfilling the diagnostic criteria for sec-
ondary SS has been noticed by Fujita et al.15 who found 
it in 90% of non-SS RA patients. In their study of 72 RA 
Japanese patients, just 10% of them had Secondary SS. 
 e presence of secondary SS in RA has been found to be 
higher in other studies. Cimmino et al.5 found it in 17.5% 
of Italian RA patients and Martinez Castro et al.6, in 55% of 
Spanish RA population.  is high variability may be due 
to the genetic background of the studied population and 
methods chosen to evaluate glandular dysfunction. 
Secondary SS is usually included as an extra-articular 
manifestation of rheumatoid arthritis16. According to Fox 
et al.17, SS associated with RA occurs in a dierent genetic 
background than the primary disease (HLA DR4) and this 
author suggests that SS associated with RA has a dierent 
pathogenetic process than that associated with lupus and 
with scleroderma. As we found in the present work, this 
later author noticed that ocular symptoms of dryness are 
more common than oral ones in RA patients. 
Our results also show that neither secondary SS occur-
rence nor eye sicca subjective and objective findings have 
any relation to disease duration. A study done in Spain 
found that patients with RA duration up to 10 years had a 
prevalence of secondary SS of 17% and aer 30 years it was 
as high as 25%18.  is relationship with disease duration 
was not confirmed by Uhlig et al.19 but was present in a 
Study done in the United Kingdom20.
 e association between secondary SS and disease ac-
tivity was also studied by Fujita et al.15 who found that RA 
activity had no significant correlation with the presence of 
dry eye, however it had some relationship in those patients 
that fulfilled the diagnosis of secondary SS. Although we 
did not graduate severity of sicca findings, we could not 
find a higher RA activity measured by DAS-28 in patients 
with secondary SS when compared to those without it in 
the present study. No relationship could also be established 
with functional index. Wolfe et al.21, although they did not 
study Secondary SS, found that sicca symptoms are more 
common in patients with RA with increased HAQ scores, 
pain and global severity as well as total joint replacement 
and work disability. 
According to the present findings rheumatologists and 
ophthalmologists should be aware of high indices of sicca 
symptoms in RA and seek for secondary SS independently 
of the activity or duration of rheumatoid arthritis.
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